Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Phathom Pharmaceuticals Inc
Pre-Tax Income
Phathom Pharmaceuticals Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
Pre-Tax Income
-$201.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-175%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Pre-Tax Income
$20.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pre-Tax Income
-$5.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Pre-Tax Income
-$1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Pre-Tax Income
$3.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-4%
|
|
Eli Lilly and Co
NYSE:LLY
|
Pre-Tax Income
$7.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
20%
|
CAGR 10-Years
5%
|
See Also
What is Phathom Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
-201.6m
USD
Based on the financial report for Dec 31, 2023, Phathom Pharmaceuticals Inc's Pre-Tax Income amounts to -201.6m USD.
What is Phathom Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-175%
Over the last year, the Pre-Tax Income growth was -2%. The average annual Pre-Tax Income growth rates for Phathom Pharmaceuticals Inc have been -16% over the past three years , -175% over the past five years .